Objective The objective of this study was to assess the clinical significance of increased fluorine-18-fluorodeoxyglucose ( 18 F-FDG) uptake on PET/CT in joints for evaluation of symptomatic osteoarthritis (OA) and prediction of progression.
Introduction
Osteoarthritis (OA) is a degenerative joint disease that involves cartilaginous degradation, subchondral bone sclerosis, and osteophyte formation [1] . OA affects millions of patients, resulting in mobility and pain symptoms, often involving the joints of the shoulders, hips, and knees [2] . More than one in five patients have self-reported and physician-diagnosed arthritis, and this number is expected to increase by at least 25% in the next 20 years [3, 4] . OA's effects on the large joints are particularly important, as treatment can require surgical intervention, and it is the leading cause of surgical joint replacement [5] . Currently, the diagnosis of OA is based on self-reported clinical symptoms and physical and radiographic evaluation of the affected joints [6] . Various self-reporting questionnaires exist and have been evaluated, including the Western Ontario and McMaster University Osteoarthritis (WOMAC) Index, which is the most widely used and recommended index by the WHO [7] [8] [9] . Radiographic evaluation is based on various measures, including joint space width, osteophyte formation, and subchondral sclerosis [6] . Multiple radiographic evaluation schemes have been used in the diagnosis and monitoring of OA. The Kellgren-Lawrence (K/L) grading system is a widely accepted standard radiographic measurement of joint degradation used for the radiographic diagnosis of OA [10, 11] .
OA of the major joints may be seen in patients with other morbid conditions, including those undergoing evaluation for malignant processes. Fluorine-18-fluorodeoxyglucose ( 18 F-FDG) PET has gained wide acceptance in clinical practice for staging, restaging, and identifying recurrence of several malignancies [12] [13] [14] . 18 F-FDG is a positronemitting radiopharmaceutical that accumulates at sites of increased glucose metabolism [15] . Incidental uptake of 18 F-FDG is frequently detected in the joints of patients undergoing PET evaluation and has been attributed to degenerative or inflammatory changes related to arthritis [16] [17] [18] . However, few studies have compared the symptomatic and radiologic findings of OA with 18 F-FDG uptake on PET imaging, particularly using a well-accepted questionnaire of OA diagnosis. As the clinical significance of increased 18 F-FDG uptake in the joints on PET/CT has not been well established, the purpose of this study was to evaluate the prognostic and diagnostic value of 18 F-FDG PET for the identification and classification of OA of the shoulder, hip, and knee joints.
Patients and methods

Patients
Consecutive patients undergoing routine PET/CT imaging from December 2010 to December 2012 for various oncologic indications and satisfying the inclusion/exclusion criteria were enrolled in this prospective study. The inclusion criteria were as follows: (a) agreement to complete a WOMAC Osteoarthritis Index questionnaire and (b) agreement to be imaged with PET/CT below the knees. Patients were excluded if they had indications that would interfere with 18 F-FDG uptake measurements of the joint spaces, including known primary bone tumors, osseous metastases, Paget's disease, gout or hyperuricemia, rheumatoid arthritis, seronegative spondyloarthropathy, infectious arthritis, joint infection, previous osseous surgery or serious trauma of the evaluated joints, history of hypercalcemia or hyperparathyroidism, known collagen disorders, or glucose of more than 200 mg/dl [19] [20] [21] [22] [23] [24] [25] [26] . This HIPAA-compliant study was approved by the Institutional Review Board and the Radiation Safety Committee. All patients undergoing PET/CT imaging at our institution signed informed consent documents.
Self-assessment of symptomatic osteoarthritis
Patients were provided with a WOMAC, version LK3.1 questionnaire, combined with a self-assessment of shoulder osteoarthritis (SASO) questionnaire. The patients were asked to complete the questionnaires with questions divided into three sections: pain, stiffness, and physical function, for shoulders, hips, and knees. The Likert grading scale was used in both the WOMAC and SASO questionnaires with the following possible scores and responses: (0) none, (1) mild, (2) moderate, (3) severe, and (4) extreme. Sums of scores were calculated for each section.
PET/CT imaging
Patients were instructed to fast for 6 h before injection of the fluorine- F-FDG radiopharmaceutical injection. The patients underwent PET/ CT imaging using a Discovery VCT 64-slice multidetector scanner (General Electric Healthcare, Waukesha, Wisocnsin, USA). A computed tomography (CT) scout image was obtained and included the top of the skull to below the knees. A low mA CT scan was then performed for attenuation correction of the PET images using a lowdose protocol (30-100 mAs, 140 kV, slice thickness of 3.7 mm), extending to include the entire knees. Static, three-dimensional PET emission images were acquired (2-3 min/bed position). Transaxial, coronal, and sagittal images were corrected for dead-time, decay, and photon attenuation, and reconstructed in a 128 × 128 matrix. The images were reconstructed using two iterations and 20 subsets with a 6.0 mm full-width half-maximum postfilter and a fully three-dimensional maximum likelihood orderedsubset expectation maximization reconstruction algorithm.
Radiographic and 18 F-FDG PET/CT evaluation of joints
CT scout images were reviewed by two radiologists (4 years of experience and 2 years of experience) using AGFA Impax 6 (Agfa-Gevaert N.V., Mortsel, Belgium) to evaluate knee, hip, glenohumeral (GH), and acromioclavicular (AC) joints. Inconclusive findings were discussed with a third radiologist (over 10 years of experience) until agreement was reached. A modified K/L grading system was used to evaluate and score arthritic changes in the shoulders, hips, and knees to more closely approximate the Likert grading scale of the WOMAC questionnaire, as follows: (0) None -no degenerative changes; (1) Mild -minimal joint space narrowing (JSN) and/or early osteophyte formation (peaking of the tibial eminences); (2) Moderate -mild JSN, marginal osteophytosis, and early subchondral sclerosis and/or cyst formation (curtain osteophytes on the femoral head or neck); (3) Severe -moderate JSN, marginal osteophytosis, and more advanced subchondral sclerosis and cyst formation, + / − presence of intra-articular bodies; (4) Extreme -severe JSN, altered clavicular, acromial morphology, humeral, glenoid, femoral, acetabular, and/or tibial morphology.
The two radiologists reviewed coregistered PET/CT images at least 2 weeks before or after reviewing the CT scout images. Joint spaces were identified in the AC, GH, hip, and knee joints on coronal PET/CT images, and maximal standardized uptake values (SUV) normalized for body mass were measured in each joint by thresholding the PET images.
In March 2016, all patient medical records and images available on Picture Archiving and Communication System were reviewed by the two radiologists blinded to PET and K/L grading system findings to evaluate for progression of OA using available radiographs, CT scout images, and MRI images. An increase in K/L grading system or placement of new prosthesis constituted progression of OA. Inconclusive findings were discussed with the third radiologist until agreement was reached. The time from PET/CT imaging to OA progression was recorded.
Statistical analysis
Mean K/L grading system scores and mean SUVs between the two observers were used in subsequent analyses. Pearson's correlation coefficients and P values were calculated between the SUV and K/L, WOMAC pain, stiffness, physical function, and overall scores using Matlab Statistics and Machine Learning Toolbox (MathWorks, Natick, Massachusetts, USA).
Receiver operating characteristic (ROC) curves and respective areas under the curves (AUCs) were estimated using SPSS Statistics (IBM Corporation, Armonk, New York, USA) for SUV and K/L in GH, AC, hip, and knee joints for detection of joint pain, decreased function and stiffness, and overall symptomatic OA. Decision thresholds for the calculation of AUCs in the detection of symptomatic OA were based on setting WOMAC zscores at 0, 1, and 2.
A Cox proportional hazards model was generated with Matlab to determine predictors of OA progression by independently and then simultaneously entering patient age, SUV, K/L, age, and WOMAC total score into the analysis for knee joints. Hazard ratios (HR) and P values were calculated. Kaplan-Meier curve was generated for SUV of the knee joints with Matlab.
Interobserver agreement between the two radiologists was evaluated for SUV (categories SUV ≥ 2 and SUV < 2, based on outcome results) and for K/L (categories grade 0-4) using Cohen's κ-coefficient with SPSS Statistics (IBM Corporation, Armonk, New York, USA).
Results
Patients and joints evaluated
Seventy-nine patients agreed to participate in the study, complete the WOMAC survey, and undergo PET/ CT imaging that included the knees. Four patients were excluded because of bone metastases. One patient was excluded because of an overactive bone marrow observed on image analysis, which obscured the SUV findings within the joint space. 
Interobserver agreement and correlations
Interobserver agreement was moderate for SUV in assessment of the knees, and substantial for SUV in evaluation of all other joints, as seen in Table 1 . With the exception of WOMAC stiffness scores for AC and GH joints, all WOMAC scores correlated with joint SUVs, as depicted in Table 2 . Furthermore, SUV correlated with K/L for all joints other than GH. Except for SUV of the hips, the SUV and K/L measurements correlated with age for all joints, as shown in Table 3 .
ROC AUC and outcome results
SUV and K/L ROC AUCs for WOMAC pain, stiffness, physical function, and total scores are shown in Tables 4-7 for all joints examined. With decision thresholds set at WOMAC z-scores of 2, largest ROC AUCs for SUV were observed in the knee joints for WOMAC overall and pain results (AUC = 0.743) and in the hips for WOMAC overall results (AUC = 0.678). Largest ROC AUCs for K/L were observed in the knee joints for WOMAC overall and pain results (AUC = 0.783 and 0.845). Follow-up imaging was available for 19 knee joints. OA progressed in six knee joints and was stable in 13. SUV (HR = 5.653, P = 0.0229), K/L score (HR = 0.798, P = 0.5324), Age (HR = 0.992, P = 0.8978), and WOMAC score (HR = 1.089, P = 0.1265) variables were entered simultaneously into the Cox proportional hazards model, and only SUV was found to be an independent predictor of OA progression in the knees. A Kaplan-Meier curve was generated to depict progression of OA in the knees over time for patients with SUV less than 2 and SUV of at least 2, as shown in Fig. 1 . Figure 2 shows 
Discussion
This study assessed the diagnostic performance of increased 18 F-FDG uptake on PET/CT in the joints for evaluation of OA. In the 130 knee joints studied, both SUV and K/L exhibited high to moderate utility for detection of symptomatic joint dysfunction related to OA. SUV showed an ROC AUC of 0.734 for detection of overall knee joint dysfunction and also for identification of joint pain based on the WOMAC questionnaire. Similarly, Hong et al. [27] studied changes on PET/CT in 166 knees, showing that SUV mean of joint and the intraarticular SUV max exhibit higher values in clinical and radiological OA than in normal joints (P < 0.01). In the 130 hip joints and 124 AC and GH joints included in this study, the SUV exhibited moderate utility for detection of symptomatic joint dysfunction related to OA, and K/L score showed moderate to low utility. SUV ROC AUCs in the hips were greater or equal to 0.65 for all WOMAC scores. Previous studies, for example by Kobayashi et al. [28, 29] , have proved that 18 F-FDG PET shows a significantly higher SUV max for progressive-stage OA cases with higher K/L than for early-stage cases, and significantly higher SUV max in cases with severe pain. However, these authors did not explore the relationship between 18 F-FDG uptake and K/L or symptoms to compare with our results. Overall, little work has been carried out to assess the significance of 18 F-FDG uptake in the joints, and our results show that SUV could serve as a useful inflammation activity index in the assessment of symptomatic OA.
OA can be diagnosed with reasonable certainty on the basis of history and physical examination, while radiographs may be used to confirm the diagnosis [30, 31] . Because of greater cost of PET/CT compared with radiographs, it would be much less likely for 18 F-FDG SUV to be used as a screening tool or first-line imaging test compared with less expensive modalities for the diagnosis of OA, particularly when the symptoms are mild. Instead, a potential role of 18 F-FDG PET/CT could be to improve localization of painful abnormalities in the inflamed joints, to direct individualized treatment in moderate and severe OA. In this study, the ROC AUCs were largest for 18 F-FDG PET/CT in the detection of more severe OA (greater WOMAC z-scores, Tables 4-7) , and PET images often showed focal or localized rather than diffuse uptake in the joints. Although the pathologic process of OA cannot be reversed using current clinically available therapies, symptoms can be managed with general and individualized therapies. Mild (WOMAC z-score of 0 to 1) and even moderate (WOMAC z-score of 1 to 2) OA symptoms of pain and stiffness can typically be relieved with lifestyle changes, such as weight loss and exercise as well as medications such as nonsteroidal anti-inflammatory drugs, acetaminophen, and tramadol, according to ACR guidelines [32] . For these systemic therapies, exact localization of pain within a joint is not important, and the same treatment is applied to the general patient population with mild to moderate OA. However, in patients who have failed to respond to medications or have severe OA (WOMAC z-score of 2 or greater), invasive procedures such as intra-articular corticosteroid injections, osteotomies to shift weight away from the symptomatic part of the joint, and partial or complete joint replacement may be necessary to relive the symptoms. For these invasive procedures, knowledge of the location of pain in the joint may be helpful in directing therapy and improving the effectiveness of the treatment. If a single Knee joint Kaplan-Meier curve showing progression of osteoarthritis in the knees for patients with standardized uptake value (SUV) < 2 (continuous line) and SUV ≥ 2 (dashed line). F-FDG uptake in the knee joint with standardized uptake value of 2.2. Kellgren and Lawrence (K/L) grade was 3 on PET/CT scout image (g). Four-hundred forty-one days later, weight-bearing diagnostic radiographs (h) were obtained to evaluate severe right knee pain and showed degenerative joint disease, most severe in the medial femorotibial compartment with varus angulation. Sixty-nine days later, the patient underwent total right knee arthroplasty, and the radiograph (i) showed normal appearance of the prosthesis. Western Ontario and McMaster University Osteoarthritis Index (WOMAC) scores for the right knee were as follows: pain = 3/20, stiffness = 0/8, physical function = 8/68, overall = 11/96. region within a joint, for example, is responsible for pain, that area of inflammation could potentially be localized with PET/CT at the site of most intense 18 F-FDG uptake and targeted with an injection. If surgery is required, it would be to the patient's greatest benefit to salvage as much of the native joint as possible rather than proceeding to a complete joint replacement, and 18 F-FDG PET/CT could potentially locate the inflamed region of the joint that should be replaced. Nevertheless, prospective multicenter clinical trials would be needed to assess the effectiveness of 18 F-FDG PET/CT in directing individualized therapies for severe OA.
In addition to the evaluation of diagnostic performance of SUV and K/L score on 18 F-FDG PET/CTs for detection of symptomatic OA in the joints, the aim of this study was to also assess their prognostic significance. Follow-up imaging was available for knee joints, and our results indicate that only SUV was an independent predictor of OA progression in the knees, when compared with K/L score, age, and WOMAC score. Specifically, progression of OA in the knees was greater for patients with SUV of at least 2, as shown in Fig. 1 . These results suggest that SUV may be a useful biomarker for detection of the rate of OA progression as well as symptomatic severity while the K/L score is more representative of the severity of OA at the time of imaging. Our findings are consistent with a reported rat study in which Paquet and colleagues showed that 18 F-FDG uptake increased with the progression of arthritis in a rat arthritis model. In this animal study, 18 F-FDG accumulation in arthritis reflected proliferating pannus and inflammatory activity, enhanced by inflammatory cytokines, suggesting that 18 F-FDG PET was effective for quantifying the inflammatory activity of arthritis and/or its therapeutic response [33] . This molecular mechanism may contribute to increased 18 F-FDG uptake in OA, reflecting the rate of disease progression.
The main limitation of this study was related to the method of anatomical assessment of bony changes of the joints using CT scout images, particularly for the knees, as the CT scout images are nonweight bearing. Although the K/L grading system of knee joints was originally developed for radiographic images, few patients enrolled in the study had radiographs of the joints initially available for review on Picture Archiving and Communication System. Furthermore, only coronal PET/CT images were used for measuring SUV in the joint spaces. Nevertheless, coronal images are the easiest to use to localize the region of highest 18 F-FDG uptake in the joint space.
Conclusion
Increased 18 F-FDG uptake in the joints on 18 F-FDG PET/CT could be helpful with localization of painful abnormalities in the inflamed regions of the joints to direct individualized treatment in moderate and severe OA. Furthermore, SUV measurement on 18 F-FDG PET/CT in the knees may serve as a biomarker for rate of progression of OA.
